Wavefront-guided LASIK: a safe treatment for myopia & astigmatism

Article

Wavefront-guided LASIK is a safe and efficacious way to correct moderate to high myopia and compound myopic astigmatism.

Wavefront-guided LASIK is a safe and efficacious way to correct moderate to high myopia and compound myopic astigmatism, according to a study published in the January issue of the Journal of Cataract and Refractive Surgery.

Simon R. Bababeygya and co-workers from Stanford University School of Medicine, Stanford, California, USA conducted a retrospective study which included 89 eyes of 45 patients with moderate (-6.0 to -8.0 D) and high (>-8.00 D) myopia treated with wavefront-guided LASIK using the WaveScan linked to the CustomVue system (AMO). All eyes were analyzed preoperatively and one, three, and 12 months postoperatively.

Mean age was 38.4 years ±7.14 (SD) and no eye was retreated during the study. The mean manifest refraction spherical equivalent was -8.10±0.98 D (range -6.00 to -10.63 D) preoperatively and -0.33±0.55 D (range -1.625 to 1.375 D) 12 months postoperatively. Ninety percent of the eyes were within ±1.00 D of the intended correction and 64% were within ±0.50 D. For all eyes, the safety index was 1.00 and the efficacy index, 1.18.

The results of the study confirm that the correction of moderate to high myopia and compound myopic astigmatism using wavefront-guided LASIK is both safe and effective.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.